A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD
Condition(s):Neuromyelitis Optica Spectrum Disorders; Neuromyelitis Optica; Devic’s DiseaseLast Updated:October 17, 2018Completed
Hide Studies Not Open or Pending
Condition(s):Neuromyelitis Optica Spectrum Disorders; Neuromyelitis Optica; Devic’s DiseaseLast Updated:October 17, 2018Completed
Condition(s):Intermediate Uveitis; Posterior Uveitis; Pan-uveitisLast Updated:April 28, 2017Unknown status
Condition(s):Rheumatoid ArthritisLast Updated:March 25, 2019Completed
Condition(s):Myasthenia Gravis, GeneralizedLast Updated:January 22, 2024Recruiting
Condition(s):Rheumatoid ArthritisLast Updated:August 1, 2017Completed
Condition(s):Immune-related Adverse Events; Advanced Solid TumorLast Updated:April 11, 2022Recruiting
Condition(s):Hepatocellular CarcinomaLast Updated:April 25, 2017Withdrawn
Condition(s):Adamantinomatous Craniopharyngioma; Recurrent Adamantinomatous CraniopharyngiomaLast Updated:January 11, 2024Recruiting
Condition(s):Infection; Rheumatoid ArthritisLast Updated:September 10, 2020Unknown status
Condition(s):Behcet Syndrome; UveitisLast Updated:March 22, 2021Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.